Four phase III studies, IMpower 133, CASPIAN, ASTRUM-005, and CAPSTONE-1, showed that programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) blockers plus chemotherapy are beneficial for untreated extensive-stage SCLC (ES-SCLC) (6–9). The gene discussed is CD274; the disease is small cell lung carcinoma.